Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: A population-based study

Neuroepidemiology

Volumn 32, Issue 1, 2008, Pages 21-29

  Zawlik, Izabela ^a,c   Vaccarella, Salvatore ^a   Kita, Daisuke ^a   Mittelbronn, Michel ^b   Franceschi, Silvia ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Glioblastoma; MGMT polymorphism; MGMT promoter methylation; TP53 mutations

Indexed keywords

ISOLEUCINE; LEUCINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENYLALANINE; PROTEIN P53; VALINE;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; FEMALE; FISHER EXACT TEST; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SURVIVAL TIME;

ADULT; AGED; BRAIN NEOPLASMS; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55449122220     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000170088     Document Type: Article

References (59)

1. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899.
2. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489.
3. 6-methylguanine. Mutagenesis 2002;17:483-487.
4. Kaina B: Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet Genome Res 2004;104:77-86.
5. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
6. 6-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N- nitrosourea. Biochem J 1975;148:521-525.
7. 6-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. Proc Natl Acad Sci USA 1974;71:639-643.
8. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh D: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-788.
9. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
10. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
12. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004;10:4933-4938.
13. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK: MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007;48:403-407.
14. Ford BN, Ruttan CC, Kyle VL, Brackley ME, Glickman BW: Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis 2000;21:1977-1981.
15. Inoue R, Abe M, Nakabeppu Y, Sekiguchi M, Mori T, Suzuki T: Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 2000;10:59-66.
16. 6-methylguanine-DNA methyltransferase. Biochemistry 1997;36:5769-5776.
17. 6-alkylguanine-DNA alkyltransferase: identification of a missense variation in the active site region. Pharmacogenetics 1999;9:81-87.
18. 6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Hum Mutat 2002;20:408-409.
19. 6-methylguanine-DNA methyltransferase (MGMT) and N-methylpurine-DNA glycosylase (MPG) in lung cancer patients from Poland. Hum Mutat 1999;14:269-270.
20. 6- alkylguanine-DNA alkyltransferase. DNA Repair (Amst.) 2007;6:1071-1078.
21. 6-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res 2002;12:335-342.
22. 6-methylguanine-DNA- methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenet Genomics 2005;15:571-578.
23. 6-Methylguanine-DNA- Methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lym phocytes of tobacco smokers. Pharmacogenet Genomics 2007;17:743-753.
24. 6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 2005;26:1473-1480.
25. 6-methylguanine-DNA methyltransferase activity: analyses of three residues at or near the methyl acceptor site. Carcinogenesis 1992;13:837-843.
26. Krzesniak M, Butkiewicz D, Samojedny A, Chorazy M, Rusin M: Polymorphisms in TDG and MGMT genes - epidemiological and functional study in lung cancer patients from Poland. Ann Hum Genet 2004;68:300-312.
27. Inoue R , Isono M, Abe M, Abe T, Kobayashi H: A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma. Neurol Res 2003;25:875-879.
28. 6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 2005;14:1774-1783.
29. Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, Liu M, Rice T, Wiencke JK, Wrensch MR: DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology 2007;29:55-58.
30. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-5958.
31. Hall J, Hashibe M, Boffetta P, Gaborieau V, Moullan N, Chabrier A, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Janout V, Fabianova E, Holcatova I, Hung RJ, McKay J, Canzian F, Brennan P: The association of sequence variants in DNA repair and cell cycle genes with cancers of the upper aerodigestive tract. Carcinogenesis 2007;28:665-671.
32. Glaab WE, Skopek TR: A novel assay for allelic discrimination that combines the fluorogenic 5′ nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay. Mutat Res 1999;430:1-12.
33. Huang J, Ye F, Chen H, Lu W, Xie X: Amino acid substitution polymorphisms of the DNA repair gene MGMT and the susceptibility to cervical carcinoma. Carcinogenesis 2007;28:1314-1322.
34. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G, Canzian F: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006;12:2101-2108.
35. Ohshima H, Bartsch H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305:253-264.
36. Kleihues P, Rajewsky MF: Chemical neurooncogenesis: role of structural DNA modifications, DNA repair and neural target cell population. Prog Exp Tumor Res 1984;27:1-16.
37. Kleihues P, Wiestler OD, Ohgaki H, Aguzzi A: Animal models of tumors of the nervous system; in Berger MS, Wilson C (eds): The Gliomas. Philadelphia, WB Saunders, 1998, pp 124-133.
38. 6-methylguanine from DNA of various mouse tissues following a single injection of N-methyl-nitrosourea. Chem Biol Interact 1977;16:325-333.
39. 6-methylguanine-DNA methyltransferase in human fetal tissues: fetal and maternal factors. Cancer Res 1987;47:51-55.
40. 6-alkylguanine- DNA alkyltransferase activity in normal human tissues and cells. Cancer Res 1984;44:2855-2857.
41. Lijinsky W: Chemistry and Biology of N-Nitroso Compounds. New York, Cambridge University Press, 1992.
42. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108.
43. Lee M, Wrensch M, Miike R: Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 1997;8:13-24.
44. Bello MJ, Alonso ME, Aminoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, de Campos JM, Gutierrez M, Isla A, Kusak ME, Lassaletta L, Sarasa JL, Vaquero J, Casartelli C, Rey JA: Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res 2004;554:23-32.
45. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005;113:581-587.
46. 6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 2003;36:23-31.
47. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C-A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-1719.
48. 6-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions. Gut 2005;54:797-802.
49. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001;61:4689-4692.
50. 6- methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001;61:8113-8117.
51. Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007;83:173-179.
52. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the Clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
53. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-1453.
54. 6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet Genomics 2006;16:469-474.
55. 6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis 2006;27:2281-2285.
56. 6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol Biomarkers Prev 2004;13:320-323.
57. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:339-342.
58. 6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal cancer in the Nurses' Health Study and Physicians' Health Study (United States). Cancer Causes Control 2006;17:721-731.
59. 6-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. Mol Cell Biol 2001;21:7105-7114.